Ardelyx completes enrollment ahead of schedule in Phase 3 ACCEL trial of IBSRELA in chronic constipation

What happened: ArdelyxDealroom has a profile for this one. Try Dealroom → announced on 3 November 2026 that it has fully enrolled, ahead of schedule, all patients in the Phase 3 ACCEL clinical trial evaluating IBSRELA (tenapanor) for the treatment of chronic idiopathic constipation (CIC) in adults — constipation with no identifiable underlying cause. Topline data are expected in the second half of 2027.

Why it matters: IBSRELA is already approved in the US for irritable bowel syndrome with constipation (IBS-C); it works locally in the gut by blocking a sodium transporter, which increases fluid in the bowel and makes stools easier to pass. ACCEL is the registration study that could extend the drug's label to the much larger chronic constipation market. Completing enrollment ahead of plan de-risks the timeline for that potential expansion.

Read more: Ardelyx via GlobeNewswire, 3 November 2026